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Haemophagocytic Ìymphohistiocytosis (HLH) is a Ìife threatening inflammatory syndrome, which
presents a highly stimulated but ineffective immune response with severe hypercytokinaemia. HLH,
primary or secondary, is characterised by prolonged fever and hepatosplenomegaly associated with
pancl.topenia, hypertriglyceridaemia nd hypofibrinogenaemia. However, the hallmark of HLH is
impaired or absent function of naturaÌ kiÌler cells and cytotoxic T Ìymphocytes. HLH presents major
diagnostic difficulties, since it may have an incomplete and/or Ìate onset and with many conditions
Ìeading to the same clinicaÌ picture. When untreated, it is fataÌ in all primary cases and in a high
percentage of acquired cases. Awareness of the clinicaÌ picture and diagnostic criteria is thus important to
start Ìife saving treatment. We describe two cases of primary HLH, with significant differences in their
clinical presentation and evolution.
*atkç r* i . t *C
Haemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory condition, with
uncontrolled proÌiferation of activated lymphocytes and histiocy'tes ecreting high amounts of
inflamn.ratory cytokines. However, this is an ineffective immune response, since there is an inpaired
function of Ìymphocytes.f HLH occurs in association with a variety of conditions (genetic or acquired)
Ìeading to the same inflammatory phenotype. Whether primary or secondary, it is characterised by
proÌonged fever and hepatosplenomegaly associated with pancytopenia, hypertriglyceridaemia nd
hypofibrinogenaemia.? Increased concentrations of cy'tokines and impaired or absent function of naturaÌ
kiÌÌer cells (NK) and cytotoxic T lymphocytes are bioÌogicaì markers of HLH.
The non-specific signs and symptoms, with multiorgan involvement and sometimes with an incomplete
and/or late onset, make HLH a disease with major diagnostic and therapeutic diff icuÌties. Diagnostic and
therapeutic guidelines, based on common clinical, laboratory and histopathologicaÌ fìndings, were
presented by the HLH Study Group of the Histiocyte Society (revised in zoo4). Altogether five of the
eight criteria (fever, splenomegaly, cytopenias, hypertrigÌyceridaemia nd/or hypofibrinogenaemia,
haemophagocytosis, low/absent NK-activity, hypeúerritinaemia and high concentrations of sIL-zr) must
be fulfilled, although patients with a moÌecular diagnosis consistent with HLH do not need to fulfil the
criteria.rì HLH is a life threatening disease, and without effective treatment and supportive care, patients
usuaÌly have a rapidÌy lethaÌ course. Immunotherapy based treatment can achieve remission; however,
haematopoietic stem ceÌÌ transpÌantation (HSCT) has been estabìished as the only curative therapy for
primary HLH.r This highlights the importance of early diagnosis, with awareness of the clinical
symptoms and diagnostic criteria.
* *s€. ;"rt',;,1ï,.r'r iirl i r,' n
Case 1
A r7-nonth-oÌd girl, with no significar.rt personal or familial medical history (non-consanguineous
parents), presented to the emergency department with a 7 day low grade fever without accompanying
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symptoms. The clinicaÌ and laboratory evaluation revealed hepatosplenomegaly and severe bicytopenia
(anaemia and thrombocytopenia), which rapidly (day ro) evoÌved to pancltopenia with various episodes
of febriÌe neutropenia. On day 39, the first severe episode of autoimmune haemoÌysis occurred,
associated with hypovolaemic shock, spÌenic enlargement and acute respiratory distress syndrome
(ARDS). On day 44,five criteria (fever, organomegaly, qtopenia, hypofibrinogenaemia nd high ferritin
concentrations) for HLH were finally present, leading to the HLH-zoo4 diagnostic and therapeutic
approach.
Çase 2
An 8-month-oÌd girl, with no significant personaÌ or famiÌiaÌ medical history (non-consanguineous
parents), presented to the emergency department with a z week Ìow grade fever without accompanying
symptoms. The cÌinicaÌ and laboratory evaluation revealed hepatosplenomegaÌy, severe pancltopenia,
hypofibrinogenaemia nd hypertriglyceridaemia. After admission, protocol for febriÌe neutropenia and
transfusion suppoft were started. On day 16, five criteria (fever, splenomegaÌy, cytopenia,
hypofibrinogenaemia/hypertrigÌyceridaemia and high ferritin concentrations) for HLH were fuÌfiÌÌed,
leading to the HLH-zoo4 diagnostic and therapeutic approach.
. " " , , * , : j ! , i - ì : :
üase 1
PCR for herpesvirus 6 was positive, but there was no seroÌogical confirmation of acute infection (IgM
negative, IgG positive). Other viraÌ and bacteriaì infections (Epstein-Barr virus (EBV), cy'tomegaÌovirus
(CMV), paruovirus B19; herpes simplex virus I/II; HN rlz; adenovirus, enterovirus and ìeishmania) were
excÌuded either by seroÌogy or poÌymerase chain reaction (PCR).
The first (day ro) histoÌogic evaluation for neoplastic disease reveaìed: myelogram with normal
morphology, cytogenetic and immunophenotypic anaÌysis and myelofibrosis on bone marrow biopsy, and
four of eight criteria for HLH. Repeated evaìuation (day ++) confirmed the diagnosis with five of eight
criteria: fever, spÌenomegaly, qtopenia (haemoglobin 2.4 g/dl, plateÌets Sooo/gl, neutrophiÌ count
3oo/mms); hypofibrinogenaemia (roo mg/dÌ); hypertrigìyceridaemia (fasting trigÌycerides +o8 me/dÌ)
and eÌevated ferritin (z7zo nglml). Direct Coombs test was strongÌy positive. Bone marrow biopsy and
myeÌogram were repeated (day +S), both showing haemophagocytosis but without myeÌofibrosis.
CerebrospinaÌ fluid analysis was normal. Further study for primary HLH revealed: eìevated sCDz5
(T.gqq U/ml), abnormal natural killer (NK) cell qtotoxicity (<10 lytic units), with normal degranulation
of these ceÌÌs. Genetic anaÌysis for PRFI, MWC-tSD and SïX-rr mutations were negative (Karolinska
Hospital, Stockholm).
Cs*e ã
DNA from parvovirus Br9 was found in the bone marrow aspirates through PCR; however, there was no
seroÌogicaÌ confirmation ofacute infection (IgM negative, IgG positive). Other viraÌ and bacteriaÌ
infections (EBV, CMV, herpes simpÌex virus 6, HIY tlz, adenovirus, enterovirus, Ìeishmania and
Mycobacterium tuberculosis) were excluded either by serology, PCR or culturaÌ assays. Initial (day z)
bone marrow (myeÌogram and bone biopsy) analysis excluded malignancy. On day 16, Ìaboratory
evaluation confirmed the diagnosis, reveaÌing five of eight criteria for HLH: fever, splenomegaly,
cy'topenia (haemoglobin 8.4 g/dÌ, pÌatelets 6ooo/pl, neutrophil count roo/mm3), hypofibrinogenaemia
(rg6 mg/dì), hypertriglyceridaemia (fasting trigÌycerides SSS mg/dì) and eÌevated ferritin (2683 ng/ml).
Repeated (day to) bone marrow biopsy and myeÌogram showed rare haemophagocltosis. Cerebrospinal
fluid analysis was normaì. Further study for primary HLH revealed: eÌevated sCDz5 (>zo ooo U/mÌ),
abnormal NK celÌ qtotoxicity and degranulation. Genetic analysis reveaÌed double heterozygosity for c-
Munc r3-4 r7pz1.Li Nonsense mutation exon 23, C.zztzC>T, causing a premature stop codon, and
spÌicing site mutation (exon/intron S) C.a88 + 5G>4, causing mRNA framing shift. This Ìast mutation
was not previously described and subsequent studies are being performed (Karolinska Hospitaì,
Stockholm).
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Infections, rheumatoÌogic disorders or maÌignancy were excluded on both cases.
l Í ' r f l i l t .1*r r r rÊ
Case ' l
Due to febrile neutropenia, various courses of broad spectrum antibiotics and antifungal treatment were
implemented. Following acute haemolysis with hypovolaemic shock and ARDS, therapy with
immunoglobulin, corticosteroids and mechanicaÌ ventilation was necessary. on day 44,
immunosuppressive therapy was initiated according to the HLHzoo4 protocol. Due to reactivation of
HLH (third week), intensifìcation therapy was instituted. On the zznd week of specifìc therapy,
haematopoietic stem celÌ transpÌantation from an HLA identicaì donor (brother, after normaÌ functional
study) with co-infusion of mesenchymatous cells was done. Preparation regimen for HSCT was done with
busuÌfan and cycÌophosphamide, and graft-versus-host disease (GVHD) prophylaxis with ciclosporin and
methotrexate (Portuguese Institute of Oncology, Lisbon).
Case 2
Due to febriÌe neutropenia, broad spectrum antibiotics and antifungal treatment were impÌemented.
Transfusion support and granulocyte colony stimulating factor (G-CSF) were started. On day r.7,
immunosuppressive therapy was init iated according to the HLH-zoo4 protocol. At the end of init ial
therapy (8 weeks), cÌinical remission was achieved. During the sixth week of continuation therapy (daily
cicÌosporin, weekÌy aÌternating dexamethasone and etoposide cycles) Ìaboratory remission was obtained:
normaì blood cell counts (haemoglobin ro.z g/dÌ, platelets 976 ooolpl, neutrophil count 3ooo/mm3),
fibrinogen (g8Z mg/dl); fasting triglycerides (248 mg/dÌ), and ferritin (265 ng/ml), Haematopoietic stem
celì transplantation was not yet performed, although an HLA identicaÌ donor was recentÌy found.
**l*trlrrt: *r ':d l *l l*w-u ::
Case J
Ten days foÌÌowing HSCT, FISH XY on blood smear revealed 96% donor cells. Presently, 18 months after
HSCT, clinicaì and Ìaboratory remission persists.
Case 2
CurrentÌy, after r8 weeks of continuation therapy, with clinical and laboratory criteria of totaÌ remission,
the patient is undergoing the preparation regimen for HSCT from a non-related donor (9/ro
histocompatibility) with co-infusion of mesenchymal cells from the father (Portuguese Institute of
OncoÌogy, Lisbon).
i.J Ì*;i: i:r;s l ':l r I
The description of these two cases, with different clinicaÌ and therapeutic outcomes, intends to reinforce
the concept of HLH as an important diagnostic consideration in cases of fever of unknown origin,l as well
as a possible cause of multiorgan faiÌure syndrome,5 as it has been recently described.
FamiÌiaÌ haemophagocytic lymphohistiocytosis (FHLH) is a group of genetically determined diseases,
with an estimated incidence of r:5o ooo live births." Most cases (85%) occur within the first year of age,
wiïh 7oo/" occurring before 6 months; however, late onset cases have also been described.,
As an autosomal recessive disease, it is more frequent in ethnic groups where consanguineous marriages
are common,r but despite its name, famiÌy history is often negative. Both our cases occurred in early
infancy (the first after the first year) and in non-consanguineous families, with no past positive medical
history.
Currently, there are four known forms of FHLH, three with causative genetic defects identified:
mutatiot'Ìs ir.r the genes encoding for perforin (PRFr), MIJNCq-4, and syntaxin rr (STX-Il). All of these
proteins are involved in cellular cytotoxicity mediated by NK and T cells.l These mutations interrupt the
exocytotic process of poÌarisation, docking, priming, and fusion in NK/cytotoxic T cells, leading to
defective cytotoxicity and subsequently HLH.: Genetic analysis of chiÌdren with primary HLH reveaÌs a
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frequency of mutations around 3o% to PRF, zo% to UNC3D and ro% to STXrr, with approxim ately 4o%
ofthe patients not having a known genetic defect.:rAccording to the literature, the double heterozygosity
for MUNC r3-4 identified in the second case had not been previously described.
AÌso, a rare finding in the first case was myelofibrosis on bone marrow biopsy and autoimmune
haemoÌytic anaemia (AIHA), both previousÌy described in association with HLH.'- "' Myelofibrosis in
childhood may be primary or secondary to infections, dmgs, toxins, autoimmune conditions,
malignancies and trauma. However, it is most often associated with haematoÌogic malignancies. The
underÌying mechanisms of bone marrow fibrosis are not fully understood, but evidence suggests that it is
mediated through numerous cytokines and growth factors. Thus, the deveÌopment of reversibÌe (with
immunosuppressive therapy) myelofibrosis in HLH (as it happened in our case) is conceivable in the
setting of a hyperinflammatory state.$ In our case, myelofibrosis may be a primary effect of HLH, or
secondary to a precipitating infectious agent such as HSV6 or autoimmunity. The cytokine
overproduction in HLH might aÌso be responsibÌe for AIHA, since the mononuclear phagocytic system
participates in the destruction of opsonised erythrocytes.:1)
Due to non-specific symptoms and signs, the diagnosis of HLH is difficult, and aÌthough the initial
ciinical presentation is highìy variabÌe, prolonged fever (up to roo%) and hepatospÌenomegaÌy (So-go%)
are the most frequent signs.a,it In these two cases, these signs were present from the onset ofthe disease.
The main differential diagnosis is a normal infection in an immune competent patient, but it is the
severity and progression of symptoms that are important for differentiation.!Ì When a patient presents
with proÌonged fever unresponsive to antibiotics, hepatospÌenomegaÌy and cy'topenias, HLH shouìd be
considered. There is evidence that some patients do not meet all the diagnostic criteria and that many
patients do so only late in the course of the disease, as in case r, with five of eight criteria presenting only
44 days after the onset of disease. Furthermore, patients with a moÌecular diagnosis consistent with HLH
do not need to fulfìÌ the diagnosis criteria to start adequate therapy.:r
FHLH is a fatal disease with a median survival of <z months after diagnosis if untreated; mortaìity occurs
mainÌy as a resuÌt of haemorrhage or opportunistic infections,'Ì but is also due to multiorgan faiÌure.
The immediate aim in treatment is to suppress severe hyperinflammation, using drugs that neutralise the
functions of activated macrophages/histiocytes and T celÌs.';ì Current treatment incÌudes
chemotherapeutic (etoposide) regimens in association with dexamethasone and cicìosporin A.:ÌThe
second aim is to remove the infectious stimuÌus for the ongoing activation of cytotoxic cells; however,
appropriate antimicrobial treatment wilÌ only sometimes modif, the course of the disease. The ultimate
aim is stem cell transpÌantation to correct the defective immune system by providing normally
functioning cells. At present, HSCT is the only curative treatment, and partiaÌ chimerism appears to be
sufficient to prevent reactivation of HLH in most cases.i The follow-up study of HSCT in chiÌdren treated
with protocoÌ HLH-94 reveaÌed that marrow transplantation using matched related or unrelated donors
offers a similar Ìong term disease-free outcome (approximately 7oo/o at 3 years), However, the success of
HSCT depends on the extent of control of HLH before transpÌantation.r'r::r Despite reactivation of HLH on
the third week of protocol HLH-o4, HSCT from a matched sibling was performed successfulÌy in our first
case.
The clinicaÌ outcome in HLH patients often depends on how fast and accurateÌy the diagnosis is
established. Therefore awareness of the clinicaÌ symptoms and diagnostic criteria is crucial to start
appropriate therapy, which has changed the prognosis from uniformÌy fatal to a cure rate of )goo/o.'':
Laarning p*il 'rts
. In cases of proÌonged fever unresponsive to antibiotics, hepatosplenomegaly and cytopenias,
haemophagocytic Ìymphohistiocytosis (HLH) shouÌd be considered.
. HLH might present as muÌtipÌe organ dysfunction syndrome.
. It is important that paediatricians and paediatric intensivists know about the diagnostic criteria
and possibÌe cìinicaÌ presentations of HLH so that treatment is promptÌy initiated
. Haematopoietic stem celÌ transpÌantation is the only curative treatment.
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